CTRI/2012/03/002527招募中2 期
Clinical Evaluation of Vyoshadi Guggulu and Haritaki Churna in the Management of Obesity (Sthaulya). - IMCRP- OB - 2010 - 2011
Central Council for Research in Ayurvedic Sciences CCRAS0 个研究点目标入组 150 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. BMI >=30 kg/m2 and < 40 kg/m2
- •2. Willing and able to participate in the study for 16 weeks.
排除标准
- •1. Intake of over the counter weight loss agents, centrally acting appetite suppressants in the previous six months.
- •2. Pathophysiologic/ genetic syndromes associated with obesity (Cushingâ??s syndrome, Turnerâ??s syndrome, Prader willi syndrome).
- •3. Patients with evidence of malignancy
- •4. Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%)
- •5. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg)
- •6. Patients on prolonged ( > 6 weeks) medication with corticosteoids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
- •7. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.)
- •8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome,
- •Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
- •9. Symptomatic patient with clinical evidence of Heart failure.
- •10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino
- •Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin,
- •Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders
- •(defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled
- •Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any
- •other condition that may jeopardize the study.
- •11. Alcoholics and/or drug abusers.
- •12. Prior surgical therapy for obesity
- •13. H/o hypersensitivity to any of the trial drugs or their ingredients.
- •14. Pregnant / lactating woman.
- •15. Patients who have completed participation in any other clinical trial during the past six (06) months.
- •16. Any other condition which the Principal Investigator thinks may jeopardize the study.
研究者
相似试验
招募中
2 期
A clinical study to see the effect of some Ayurvedic formulations in the management of ObesityCTRI/2012/01/002377Department of AYUSH Ministry of Health Family Welfare Government of India150
招募中
2 期
A clinical study to see the effect of some Ayurvedic formulations in the management of Lipid disorders.CTRI/2012/01/002374Department of AYUSH Ministry of Health Family Welfare Government of India150
招募中
2 期
A clinical study to see the effect of some Ayurvedic formulation in the management of Lipid Disorders.CTRI/2012/03/002528Central Council for Research in Ayurvedic Sciences CCRAS150
尚未招募
1 期
A Clinical Trial to study the effect of tablet Vyoshadi guggulu along with the Vaitarana Basti protocol in Rheumatoid Arthritis.CTRI/2023/06/054110Dr Nagashree
招募中
3 期
CLINICAL EVALUATION OF VYOSHADI GUGGULU AND PANCHASAMA CHURNA IN AMAVATA (RHEUMATOID ARTHRITIS)CTRI/2014/12/005331CENTRAL COUNCIL FOR RESEARCH IN AYURVEDIC SCIENCES90